Caris Life Sciences, Inc.
CAI
$18.43
-$0.05-0.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | 125.44% | 113.38% | 81.31% | 49.88% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 125.44% | 113.38% | 81.31% | 49.88% | |
| Cost of Revenue | 21.77% | 21.18% | 8.35% | 17.02% | |
| Gross Profit | 207.93% | 232.13% | 202.72% | 118.51% | |
| SG&A Expenses | 23.44% | 20.14% | 33.65% | 9.51% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 22.47% | 13.37% | 19.35% | 3.45% | |
| Operating Income | 338.65% | 153.65% | 73.16% | 37.16% | |
| Income Before Tax | 321.82% | 135.92% | -8.47% | 7.61% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 321.82% | 135.92% | -8.47% | 7.61% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 321.82% | 135.92% | -8.47% | 7.61% | |
| EBIT | 338.65% | 153.65% | 73.16% | 37.16% | |
| EBITDA | 431.32% | 174.56% | 79.10% | 31.69% | |
| EPS Basic | 116.72% | 103.33% | -213.88% | 6.12% | |
| Normalized Basic EPS | 128.71% | 104.54% | 55.66% | 8.41% | |
| EPS Diluted | 115.98% | 103.09% | -213.88% | 6.12% | |
| Normalized Diluted EPS | 127.35% | 104.31% | 55.66% | 8.41% | |
| Average Basic Shares Outstanding | 691.44% | 691.44% | 83.54% | 0.88% | |
| Average Diluted Shares Outstanding | 730.35% | 733.84% | 83.54% | 0.88% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |